Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Total Current Liabilities (2020 - 2026)

Unicycive Therapeutics filings provide 4 years of Total Current Liabilities readings, the most recent being $24.1 million for Q4 2024.

  • On a quarterly basis, Total Current Liabilities rose 37.56% to $24.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $24.1 million, a 37.56% increase, with the full-year FY2024 number at $24.1 million, up 37.56% from a year prior.
  • Total Current Liabilities hit $24.1 million in Q4 2024 for Unicycive Therapeutics, up from $10.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $30.3 million in Q1 2024 to a low of $2.1 million in Q4 2021.
  • Median Total Current Liabilities over the past 4 years was $13.1 million (2024), compared with a mean of $12.2 million.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 564.86% in 2023 and later tumbled 32.33% in 2024.
  • Unicycive Therapeutics' Total Current Liabilities stood at $2.1 million in 2021, then soared by 56.01% to $3.3 million in 2022, then soared by 433.92% to $17.5 million in 2023, then soared by 37.56% to $24.1 million in 2024.
  • The last three reported values for Total Current Liabilities were $24.1 million (Q4 2024), $10.5 million (Q3 2024), and $13.1 million (Q2 2024) per Business Quant data.